The Oncomine Dx Target Test assesses tumor samples for the presence of biomarkers associated with three drug therapies approved to treat non-small cell lung cancer.
Physicians can use the test to identify the ideal therapy option for each patient, based on his or her own biomarkers.
Thermo Fisher Scientifics will roll out the test to several laboratories across the country, including Burlington N.C.-based LabCorp; Fort Myers, Fla.-based NeoGenomics Laboratories; and Rutherford, N.J.-based Cancer Genetics.
More articles on supply chain:
Viewpoint: 4 insights into postapproval monitoring of medical devices
6 drugmakers in the headlines
Philips acquires noninvasive neurodiagnostics company for $36M
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
